Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, discusses insights from the WSG TP-II trial regarding the impact of pathological complete response (pCR) and HER2 protein expression on prognosis in HER2-positive breast cancer. The trial found no significant correlation between pCR or additional chemotherapy and long-term outcomes, likely due to the efficacy of dual HER2 blockade in all patients. Dr. Gluz highlights the importance of evaluating HER2 protein levels, noting that patients with high HER2 expression are more likely to achieve early pCR, and suggests that future research should explore distinct treatment approaches based on HER2 expression levels. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
